tag:blogger.com,1999:blog-5068743626565397624.post4376977358827284938..comments2024-03-19T13:15:57.087-07:00Comments on Prostate Cancer News, Reviews & Views: Why Lutetium-177-PSMA treatment sometimes may not help, and may even harmAllenhttp://www.blogger.com/profile/02930631057044153073noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-5068743626565397624.post-1890990925160476712022-07-22T14:56:31.959-07:002022-07-22T14:56:31.959-07:00Email Michael Hofman's studies to your oncolog...Email Michael Hofman's studies to your oncologist with a short note saying you'd like to discuss it at your next meeting.Allenhttps://www.blogger.com/profile/02930631057044153073noreply@blogger.comtag:blogger.com,1999:blog-5068743626565397624.post-16971051062238796712022-07-22T13:50:02.004-07:002022-07-22T13:50:02.004-07:00Thanks for this analysis. Are there any specific h...Thanks for this analysis. Are there any specific hospitals or specific doctors that have a grasp of the information you detailed in this post? It seems like most doctors don't have an understanding of the specific details you provided us, and therefore, their recommendations are less than optimal.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-5068743626565397624.post-72808830130266931662020-03-16T08:17:28.983-07:002020-03-16T08:17:28.983-07:00The following may add to the discussion:
Eur J Nu...The following may add to the discussion: <br />Eur J Nucl Med Mol Imaging. 2020 Mar 5. doi: 10.1007/s00259-020-04723-z. [Epub ahead of print]<br />Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.<br />Ferdinandus J1,2, Violet J3, Sandhu S4,5, Hicks RJ2,5, Ravi Kumar AS2,5, Iravani A2,5, Kong G2,5, Akhurst T2,5, Thang SP2, Murphy DG5,6, Williams S3,5, Hofman MS7,8.<br />Author information<br />Abstract<br />PURPOSE:<br /><br />We analysed quantitative biomarkers derived from both baseline whole-body imaging and blood serum to identify prognostic markers in patients treated within the lutetium-177 prostate-specific membrane antigen (LuPSMA) phase 2 trial.<br />METHODS:<br /><br />PET image analysis was carried out using whole-body segmentation quantifying molecular tumour volume (SUV > 3 threshold for PSMA, SUV > liver+2sd for fluorodeoxyglucose (FDG) including SUVmax and SUVmean. For baseline bone scans, EXINI bone scan index (BSI) was used to calculate the percentage of involved bone. Baseline alkaline phosphatase (ALP), lactate dehydrogenase (LDH), prostate specific antigen (PSA) and PSA doubling time were also used in this analysis. We used univariate cox regression analysis and log-rank comparison with optimised cut-offs to find suitable biomarkers prognostic of overall survival from time of enrolment.<br />RESULTS:<br /><br />This analysis identified FDG-positive tumour volume (FDGvol; HR 2.6; 95% CI, 1.4-4.8), mean intensity of PSMA-avid tumour uptake (PSMAmean; HR 0.89; 95% CI, 0.8-0.98), bone scan index (BSI; HR 2.3; 95% CI, 1.2-4.4), ALP (HR 1.1; 95% CI, 1-1.2) and LDH (HR 1.2; 95% CI, 1-1.5) as biomarkers prognostic of overall survival.<br />CONCLUSIONS:<br /><br />In addition to established biomarkers, both FDG and PSMA PET/CT parameters have prognostic significance for survival in men undergoing LuPSMA therapy.<br />KEYWORDS:<br /><br />FDG; PSMA; Prognostic markers; Prostate cancer; Prostate specific membrane antigen; Radioligand therapy; Theranostics<br /><br />PMID:<br /> 32140802<br />DOI:<br /> 10.1007/s00259-020-04723-z Anonymoushttps://www.blogger.com/profile/15703494575596829440noreply@blogger.comtag:blogger.com,1999:blog-5068743626565397624.post-75663469195569615942020-02-05T08:26:08.149-08:002020-02-05T08:26:08.149-08:00Extremely informative. Thank you so much!Extremely informative. Thank you so much!KimmyBhttps://www.blogger.com/profile/10454711891766233703noreply@blogger.comtag:blogger.com,1999:blog-5068743626565397624.post-33533046105518337142020-01-19T14:14:35.122-08:002020-01-19T14:14:35.122-08:00This is excellent and I second Alan's comment....This is excellent and I second Alan's comment. There is very little competent and balanced commentary in the field of prostate cancer research and trials. I value your comments and opinions. I know it takes a lot time to review this material and to understand it. So...many thanks. Cheers, Phil Anonymoushttps://www.blogger.com/profile/15703494575596829440noreply@blogger.comtag:blogger.com,1999:blog-5068743626565397624.post-78236847325618762172019-12-17T10:23:13.968-08:002019-12-17T10:23:13.968-08:00Very informative. Thanks.Very informative. Thanks.Alanhttps://www.blogger.com/profile/14110458884502575678noreply@blogger.com